TCR DOMAINS IN T CELL DIFFERENTIATION AND PATHOPHYSIOLOGICAL AND THERAPEUTIC RESPONSES

Our research focuses on understanding the mechanisms by which T cells recognize antigens presented by Major Histocompatibility Complex (MHC) molecules and how this recognition activates immune responses. We investigate the organization of T cell receptors (TCRs) into nanoclusters, which allows T cells to become activated even with few peptide-bound MHC molecules. Our goal is to apply this knowledge to develop improved versions of recombinant immune receptors for cancer immunotherapy. We also study the molecular processes underlying TCR signaling and its impact on T cell development and autoimmune responses. Furthermore, we've developed innovative strategies to engineer CAR-T cells for cancer therapy, including a logical gating system to target leukemia while avoiding toxicity.